Sigh....If you look at the thread from when the topline results...

Sigh....

If you look at the thread from when the topline results came out, you will see these things discussed ad nauseum. The data analysis plan would include a prespecified analysis for under and over 65s. Data analysis plan done in advance, FDA would have access even if the data analysis plan isn't provided in clinicaltrials.gov. You would normally only see it in clinicaltrials.gov if they planned on using age in the selection process, ie, stratifying the population by age, separate arms, etc. Followup trial would show the breakdown in clinical trials.gov because you would have different treatment arms getting different dosage depending on age.

As for excluding over 65s from the start, well... they were dying at a very high rate, and NIH was providing funding in a quest to find treatments for an emergency situation. They weren't about to exclude those most in need.